Antidepressant-like effect of the norepinephrine-dopamine reuptake inhibitor bupropion in a mouse model of Huntington's disease with dopaminergic dysfunction

Journal of Huntington's Disease

Volumn 1, Issue 2, 2012, Pages 261-266

  Renoir, Thibault ^a   Argyropoulos, Andrew ^a   Hannan, Anthony J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

behaviours; bupropion; depression; dopamine; Huntington's disease; mouse model

Indexed keywords

AMFEBUTAMONE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; ANTIDEPRESSANT AGENT; DOPAMINE UPTAKE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG EFFECT; FEMALE; FORCED SWIMMING TEST; HUNTINGTON CHOREA; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANIMAL BEHAVIOR; DOSE RESPONSE; DRUG EFFECTS; HUNTINGTON DISEASE; PATHOPHYSIOLOGY; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BUPROPION; DEPRESSION; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUNTINGTON DISEASE; LOCOMOTION; MALE; MICE; MICE, TRANSGENIC; TREATMENT OUTCOME;

EID: 84930189129     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-120039     Document Type: Article

References (47)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72(6):971-83.
2. Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC. Psychiatric symptoms in Huntington's disease before diagnosis: The predict-HD study. Biol Psychiatry. 2007;62(12): 1341-6. (Pubitemid 350180721)
3. Julien CL, Thompson JC, Wild S, Yardumian P, Snowden JS, Turner G, et al. Psychiatric disorders in preclinical Huntington's disease. J Neurol Neurosurg Psychiatry. 2007;78(9):939-43. (Pubitemid 47310828)
4. Marshall J, White K, Weaver M, Flury Wetherill L, Hui S, Stout JC, et al. Specific psychiatric manifestations among preclinical Huntington disease mutation carriers. Arch Neurol. 2007;64(1):116-21. (Pubitemid 46072433)
5. Paulsen JS, Nehl C, Hoth KF, Kanz JE, Benjamin M, Conybeare R, et al. Depression and stages of Huntington's disease. J Neuropsychiatry Clin Neurosci. 2005;17(4):496-502. (Pubitemid 41790050)
6. Thompson JC, Harris J, Sollom AC, Stopford CL, Howard E, Snowden JS, et al. Longitudinal evaluation of neuropsychiatric symptoms in Huntington's disease. J Neuropsychiatry Clin Neurosci. 2012;24(1):53-60.
7. Thompson JC, Snowden JS, Craufurd D, Neary D. Behavior in Huntington's disease: Dissociating cognition-based and mood-based changes. J Neuropsychiatry Clin Neurosci. 2002;14(1):37-43. (Pubitemid 34117021)
8. Andrews TC,Weeks RA,Turjanski N, Gunn RN,Watkins LH, Sahakian B, et al. Huntington's disease progression. PET and clinical observations. Brain. 1999;122(Pt 12):2353-63.
9. Ginovart N, Lundin A, Farde L, Halldin C, Backman L,Swahn CG, et al. PET study of the pre-and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain. 1997;120(Pt 3):503-14. (Pubitemid 27153642)
10. Pavese N, Politis M,Tai YF, Barker RA,Tabrizi SJ, Mason SL, et al. Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiol Dis. 2010;37(2):356-61.
11. Pang TY, Du X, Zajac MS, Howard ML, Hannan AJ. Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease. Hum Mol Genet. 2009;18(4): 753-66.
12. Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersen A, et al. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain. 2009;132(Pt 4): 919-32.
13. Orvoen S, Pla P, Gardier AM, Saudou F, David DJ. Huntington's disease knock-in male mice show specific anxiety-like behaviour and altered neuronal maturation. Neurosci Lett. 2012;507(2):127-32.
14. Renoir T, Pang TY, Hannan AJ. Effects of environmental manipulations in genetically targeted animal models of affective disorders. Neurobiol Dis. 2012 Apr 16. [Epub ahead of print] .
15. Renoir T, Pang TY, Lanfumey L. Drug withdrawal-induced depression: Serotonergic and plasticity changes in animal models. Neurosci Biobehav Rev. 2012;36(1):696-726.
16. Renoir T, Chevarin C, Lanfumey L, Hannan AJ. Effect of enhanced voluntary physical exercise on brain levels of monoamines in Huntington disease mice. PLoS Currents. 2011;3:RRN1281.
17. Renoir T, Pang TY, Zajac MS, Chan G, Du X, Leang L, et al. Treatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise. Br J Pharmacol. 2012;165(5):1375-89.
18. Renoir T, Zajac MS, Du X, Pang TY, Leang L, Chevarin C, et al. Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington's disease and depression. PloS One. 2011;6(7):e22133.
19. Haenisch B, Bonisch H. Depression and antidepressants: Insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters. Pharmacol Ther 2011; 129(3):352-68.
20. Ruhe HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: A meta-analysis of monoamine depletion studies. Mol Psychiatry. 2007;12(4):331-59. (Pubitemid 46496835)
21. Corcoran C, Wong ML, O'Keane V. Bupropion in the management of apathy. J Psychopharmacol. 2004;18(1):133-5. (Pubitemid 38623107)
22. Nutt D, Demyttenaere K, Janka Z, Aarre T, Bourin M, Canonico PL, et al. The other face of depression, reduced positive affect: The role of catecholamines in causation and cure. J Psychopharmacol. 2007;21(5):461-71. (Pubitemid 47106935)
23. Kennedy L, Shelbourne PF,Dewar D. Alterations in dopamine and benzodiazepine receptor binding precede overt neuronal pathology in mice modelling early Huntington disease pathogenesis. Brain Res. 2005;1039(1-2):14- 21. (Pubitemid 40386822)
24. Kung VW, Hassam R, Morton AJ, Jones S. Dopaminedependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington's disease. Neuroscience. 2007;146(4):1571-80. (Pubitemid 46783231)
25. Mochel F, Durant B, Durr A, Schiffmann R. Altered dopamine and serotonin metabolism in motorically asymptomatic R6/2 mice. PloS One. 2011;6(3):e18336.
26. Ortiz AN, Kurth BJ, Osterhaus GL, Johnson MA. Dysregulation of intracellular dopamine stores revealed in the R6/2 mouse striatum. J Neurochem. 2010;112(3):755-61.
27. Glass M, van Dellen A, Blakemore C, Hannan AJ, Faull RL. Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience. 2004;123(1):207-12. (Pubitemid 37518488)
28. Ortiz AN, Kurth BJ, Osterhaus GL, Johnson MA. Impaired dopamine release and uptake in R6/1 Huntington's disease model mice. Neurosci Lett. 2011;492(1):11-4.
29. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of theHDgene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87(3):493-506. (Pubitemid 26374323)
30. Howard ML, Palmer SJ, Taylor KM, Arthurson GJ, Spitzer MW, Du X, et al. Mutation of Gtf2ird1 from the Williams-Beuren syndrome critical region results in facial dysplasia, motor dysfunction, and altered vocalisations. Neurobiol Dis. 2012;45(3):913-22.
31. Benn CL, Luthi-Carter R, Kuhn A, Sadri-Vakili G, Blankson KL, Dalai SC, et al. Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease. J Neuropathol Exp Neurol. 2010;69(8):817-27.
32. Dowie MJ, Bradshaw HB, Howard ML, Nicholson LF, Faull RL, Hannan AJ, et al. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Neuroscience. 2009;163(1):456-65.
33. Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, Horiuchi A, et al. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci U S A. 2000;97(12):6809-14. (Pubitemid 30412796)
34. Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci U S A. 1998;95(11):6480-5. (Pubitemid 28249039)
35. Spektor BS, Miller DW, Hollingsworth ZR, Kaneko YA, Solano SM, Johnson JM, et al. Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease. Brain Res Mol Brain Res 2002;102(1-2):118-28. (Pubitemid 34607750)
36. Petit-Demouliere B, Chenu F, Bourin M. Forced swimming test in mice: A review of antidepressant activity. Psychopharmacology. 2005;177(3):245-55. (Pubitemid 40137284)
37. Porsolt RD, Bertin A, Jalfre M. "Behavioural despair" in rats and mice: Strain differences and the effects of imipramine. Eur J Pharmacol. 1978;51(3):291-4. (Pubitemid 9208063)
38. Crook ZR, Housman DE. Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice. Proc Natl Acad Sci U S A. 2012;109(19):7487-92.
39. Cummings DM, Milnerwood AJ, Dallerac GM, Waights V, Brown JY, Vatsavayai SC, et al. Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. Hum Mol Genet. 2006;15(19):2856-68. (Pubitemid 44446806)
40. Dallerac GM, Vatsavayai SC, Cummings DM, Milnerwood AJ, Peddie CJ, Evans KA, et al. Impaired long-term potentiation in the prefrontal cortex of Huntington's disease mouse models: Rescue by D1 dopamine receptor activation. Neurodegener Dis. 2011;8(4):230-9.
41. Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain. 1996;119(Pt 6):2085-95. (Pubitemid 27032638)
42. Esmaeilzadeh M, Farde L, Karlsson P, Varrone A, Halldin C, Waters S, et al. Extrastriatal dopamine D(2) receptor binding in Huntington's disease. Hum Brain Mapp. 2011;32(10):1626-36.
43. Lundin A, Dietrichs E, Haghighi S, Goller ML, Heiberg A, Loutfi G, et al. Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease. Clin Neuropharmacol. 2010;33(5):260-4.
44. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, et al. 15 years of clinical experience with bupropion HCl: From bupropion to bupropion SR to bupropion XL. Primary care companion to the Journal of Clinical Psychiatry. 2005;7(3):106-13. (Pubitemid 41783226)
45. Trivedi MH, Rush AJ, Carmody TJ, Donahue RM, Bolden-Watson C, Houser TL, et al. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psychiatry. 2001;62(10):776-81. (Pubitemid 33104664)
46. KrishnamoorthyA, Craufurd D. Treatment of Apathy in Huntington's Disease and Other Movement Disorders. Current Treatment Options in Neurology. 2011; 13(5):508-19.
47. Holl AK, Wilkinson L, Painold A, Holl EM, Bonelli RM. Combating depression in Huntington's disease: Effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol. 2010;25(1):46-50.